# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0000950170-25-088704
Filing Date
2025-06-23
Accepted
2025-06-23 07:02:41
Documents
27
Period of Report
2025-06-23
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | lrmr-20250623.htm iXBRL | 8-K | 48376
2 | EX-99.1 | lrmr-ex99_1.htm | EX-99.1 | 40238
3 | EX-99.2 | lrmr-ex99_2.htm | EX-99.2 | 20508
4 | GRAPHIC | img46574298_0.jpg | GRAPHIC | 282533
5 | GRAPHIC | lrmr-ex99_2s1.jpg | GRAPHIC | 195529
6 | GRAPHIC | lrmr-ex99_2s2.jpg | GRAPHIC | 696012
7 | GRAPHIC | lrmr-ex99_2s3.jpg | GRAPHIC | 309010
8 | GRAPHIC | lrmr-ex99_2s4.jpg | GRAPHIC | 507236
9 | GRAPHIC | lrmr-ex99_2s5.jpg | GRAPHIC | 423768
10 | GRAPHIC | lrmr-ex99_2s6.jpg | GRAPHIC | 339084
11 | GRAPHIC | lrmr-ex99_2s7.jpg | GRAPHIC | 371742
12 | GRAPHIC | lrmr-ex99_2s8.jpg | GRAPHIC | 319427
13 | GRAPHIC | lrmr-ex99_2s9.jpg | GRAPHIC | 399757
14 | GRAPHIC | lrmr-ex99_2s10.jpg | GRAPHIC | 352279
15 | GRAPHIC | lrmr-ex99_2s11.jpg | GRAPHIC | 314304
16 | GRAPHIC | lrmr-ex99_2s12.jpg | GRAPHIC | 368849
17 | GRAPHIC | lrmr-ex99_2s13.jpg | GRAPHIC | 427158
18 | GRAPHIC | lrmr-ex99_2s14.jpg | GRAPHIC | 334705
| Complete submission text file | 0000950170-25-088704.txt |  | 7973310

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
19 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | lrmr-20250623.xsd | EX-101.SCH | 23893
29 | EXTRACTED XBRL INSTANCE DOCUMENT | lrmr-20250623_htm.xml | XML | 4533

Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 251062946
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)